This event has passed

Date and Location

March 9, 2023
4:30 PM - 6:00 PM ET
B-l-4 Hauser Conference Room


HKS events calendar icon

​​The emergence of drug-resistant bacteria is a huge and threatening problem, yet the pharmaceutical and venture capital industries have not stepped forward to address it.  Why is that, and what can be done from a public policy point of view?  Hear from experts who are on the front lines of antibiotic development.

This study group / discussion is open to all. Registration is not necessary.
M-RCBG welcomes individuals with disabilities to participate in its programs. To request accommodations or ask questions about access provided, please email:

Speakers and Presenters

​Eric Evans: M-RCBG Senior Fellow

M. Kevin Outterson: Executive Director, CARB-X (Combating Antibiotic-Resistant Bacteria)

Martin F. Heidecker: Chief Investment Officer, AMR Action Fund​